On June 10, 2025 Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported that the company will present at the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts (Press release, Azitra, JUN 10, 2025, View Source [SID1234653787]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will highlight recent updates and progress in Azitra’s pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome and ATR-04, in development for the treatment of moderate to severe EGFRi-associated dermal toxicity in adults.

Details of the presentation are as follows:

Event:

2025 BIO International Convention

Date and Time:

Tuesday, June 17 at 12:00 PM, ET

Location:

Boston Convention & Exhibition Center, Room 154

Presenter:

Travis Whitfill PhD MPH, Cofounder and Chief Operating Officer

During the conference, Dr. Whitfill will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.